STOCK TITAN

[SCHEDULE 13G/A] iRhythm Technologies, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Capital Research Global Investors filed Amendment No.4 to a Schedule 13G/A reporting its holdings in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). The filing states CRGI holds 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding, with sole voting and dispositive power for that amount. The filing cites an event date of 06/30/2025 and is signed on 08/05/2025.

The filing describes CRGI as a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." The statement includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Capital Research Global Investors ha presentato l'Emendamento No.4 al Schedule 13G/A relativo alle sue partecipazioni in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). La comunicazione indica che CRGI detiene 1,506,864 azioni, pari al 4.7% delle 31,925,267 azioni ritenute in circolazione, con potere di voto e di disposizione esclusivo su tale ammontare. Il documento riporta la data dell'evento 06/30/2025 ed è firmato in data 08/05/2025.

La dichiarazione descrive CRGI come una divisione di Capital Research and Management Company e di entità correlate di gestione degli investimenti che operano sotto il nome "Capital Research Global Investors". Il documento include una certificazione secondo cui le azioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attività e non con l'intento di modificare o influenzare il controllo dell'emittente.

Capital Research Global Investors presentó la Enmienda No.4 al Schedule 13G/A que informa sobre sus participaciones en iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). La presentación indica que CRGI posee 1,506,864 acciones, que representan el 4.7% de las 31,925,267 acciones que se cree están en circulación, con poder de voto y de disposición exclusivo sobre esa cantidad. El documento cita la fecha del evento 06/30/2025 y está firmado el 08/05/2025.

La presentación describe a CRGI como una división de Capital Research and Management Company y de entidades relacionadas de gestión de inversiones que prestan servicios bajo el nombre "Capital Research Global Investors". La declaración incluye una certificación de que las acciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.

Capital Research Global Investors는 iRhythm Technologies, Inc.의 지분에 관한 Schedule 13G/A 수정서(Amendment No.4)를 제출했습니다 (Common Stock, CUSIP 450056106). 제출서에는 CRGI가 1,506,864주를 보유하고 있으며 이는 발행주식으로 추정되는 31,925,267주의 약 4.7%에 해당하고, 해당 수량에 대해 단독 의결권 및 처분권을 보유하고 있다고 기재되어 있습니다. 제출서는 사건일자를 06/30/2025로 밝히고 있으며, 서명일은 08/05/2025입니다.

해당 제출서는 CRGI를 Capital Research and Management Company의 한 부문과 "Capital Research Global Investors"라는 명칭으로 서비스를 제공하는 관련 투자운용 법인들로 설명합니다. 또한 주식은 정상적인 영업 과정에서 취득·보유된 것이며 발행회사의 지배권을 변경하거나 영향력을 행사할 목적으로 보유된 것이 아님을 인증하는 내용이 포함되어 있습니다.

Capital Research Global Investors a déposé l'Amendement No.4 au Schedule 13G/A déclarant ses participations dans iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). Le dépôt indique que CRGI détient 1,506,864 actions, représentant 4.7% des 31,925,267 actions estimées en circulation, avec le pouvoir exclusif de vote et de disposition sur ce montant. Le document fait état d'une date d'événement du 06/30/2025 et est signé le 08/05/2025.

Le dépôt décrit CRGI comme une division de Capital Research and Management Company et des entités associées de gestion d'investissements fournissant des services sous le nom "Capital Research Global Investors". La déclaration inclut une certification indiquant que les actions ont été acquises et sont détenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Capital Research Global Investors hat Nachtrag Nr. 4 (Amendment No.4) zu einem Schedule 13G/A eingereicht, der seine Beteiligungen an iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106) meldet. Die Einreichung gibt an, dass CRGI 1,506,864 Aktien hält, was 4.7% der geschätzten 31,925,267 ausstehenden Aktien entspricht, und dass es an dieser Menge über alleiniges Stimm- und Verfügungsrecht verfügt. Die Einreichung nennt das Ereignisdatum 06/30/2025 und ist am 08/05/2025 unterzeichnet.

Die Erklärung beschreibt CRGI als eine Sparte der Capital Research and Management Company und assoziierte Investment-Management-Einheiten, die unter dem Namen "Capital Research Global Investors" Dienstleistungen erbringen. Die Mitteilung enthält eine Bestätigung, dass die Aktien im gewöhnlichen Geschäftsverlauf erworben und gehalten werden und nicht zum Zweck, die Kontrolle des Emittenten zu ändern oder zu beeinflussen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: CRGI reports a 4.7% passive stake (1,506,864 shares) in IRTC; below 5% threshold, limited governance impact.

The filing discloses a non-controlling position of 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding. Voting and dispositive power are reported as sole for that exact amount, and the certification states the holdings are in the ordinary course of business and not intended to influence control. From an investment-analysis perspective, this is a notable institutional position but falls below common 5% thresholds that often trigger heightened investor scrutiny or additional disclosure obligations.

TL;DR: The filing confirms sole voting/dispositive power for 1,506,864 shares and certifies holdings not intended to influence issuer control.

The Schedule 13G/A clarifies the reporting person is Capital Research Global Investors, a division of Capital Research and Management Company and affiliated investment management entities, organized in Delaware. The report emphasizes a passive ownership stance with explicit certification that the stake was not acquired to change or influence company control. Given the 4.7% level, this position is material as an institutional holding but does not, by itself, indicate governance intentions or control actions disclosed in this filing.

Capital Research Global Investors ha presentato l'Emendamento No.4 al Schedule 13G/A relativo alle sue partecipazioni in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). La comunicazione indica che CRGI detiene 1,506,864 azioni, pari al 4.7% delle 31,925,267 azioni ritenute in circolazione, con potere di voto e di disposizione esclusivo su tale ammontare. Il documento riporta la data dell'evento 06/30/2025 ed è firmato in data 08/05/2025.

La dichiarazione descrive CRGI come una divisione di Capital Research and Management Company e di entità correlate di gestione degli investimenti che operano sotto il nome "Capital Research Global Investors". Il documento include una certificazione secondo cui le azioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attività e non con l'intento di modificare o influenzare il controllo dell'emittente.

Capital Research Global Investors presentó la Enmienda No.4 al Schedule 13G/A que informa sobre sus participaciones en iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). La presentación indica que CRGI posee 1,506,864 acciones, que representan el 4.7% de las 31,925,267 acciones que se cree están en circulación, con poder de voto y de disposición exclusivo sobre esa cantidad. El documento cita la fecha del evento 06/30/2025 y está firmado el 08/05/2025.

La presentación describe a CRGI como una división de Capital Research and Management Company y de entidades relacionadas de gestión de inversiones que prestan servicios bajo el nombre "Capital Research Global Investors". La declaración incluye una certificación de que las acciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar o influir en el control del emisor.

Capital Research Global Investors는 iRhythm Technologies, Inc.의 지분에 관한 Schedule 13G/A 수정서(Amendment No.4)를 제출했습니다 (Common Stock, CUSIP 450056106). 제출서에는 CRGI가 1,506,864주를 보유하고 있으며 이는 발행주식으로 추정되는 31,925,267주의 약 4.7%에 해당하고, 해당 수량에 대해 단독 의결권 및 처분권을 보유하고 있다고 기재되어 있습니다. 제출서는 사건일자를 06/30/2025로 밝히고 있으며, 서명일은 08/05/2025입니다.

해당 제출서는 CRGI를 Capital Research and Management Company의 한 부문과 "Capital Research Global Investors"라는 명칭으로 서비스를 제공하는 관련 투자운용 법인들로 설명합니다. 또한 주식은 정상적인 영업 과정에서 취득·보유된 것이며 발행회사의 지배권을 변경하거나 영향력을 행사할 목적으로 보유된 것이 아님을 인증하는 내용이 포함되어 있습니다.

Capital Research Global Investors a déposé l'Amendement No.4 au Schedule 13G/A déclarant ses participations dans iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). Le dépôt indique que CRGI détient 1,506,864 actions, représentant 4.7% des 31,925,267 actions estimées en circulation, avec le pouvoir exclusif de vote et de disposition sur ce montant. Le document fait état d'une date d'événement du 06/30/2025 et est signé le 08/05/2025.

Le dépôt décrit CRGI comme une division de Capital Research and Management Company et des entités associées de gestion d'investissements fournissant des services sous le nom "Capital Research Global Investors". La déclaration inclut une certification indiquant que les actions ont été acquises et sont détenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle de l'émetteur.

Capital Research Global Investors hat Nachtrag Nr. 4 (Amendment No.4) zu einem Schedule 13G/A eingereicht, der seine Beteiligungen an iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106) meldet. Die Einreichung gibt an, dass CRGI 1,506,864 Aktien hält, was 4.7% der geschätzten 31,925,267 ausstehenden Aktien entspricht, und dass es an dieser Menge über alleiniges Stimm- und Verfügungsrecht verfügt. Die Einreichung nennt das Ereignisdatum 06/30/2025 und ist am 08/05/2025 unterzeichnet.

Die Erklärung beschreibt CRGI als eine Sparte der Capital Research and Management Company und assoziierte Investment-Management-Einheiten, die unter dem Namen "Capital Research Global Investors" Dienstleistungen erbringen. Die Mitteilung enthält eine Bestätigung, dass die Aktien im gewöhnlichen Geschäftsverlauf erworben und gehalten werden und nicht zum Zweck, die Kontrolle des Emittenten zu ändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Capital Research Global Investors
Signature:Jae Won Chung
Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
Date:08/05/2025

FAQ

What ownership stake did Capital Research Global Investors report in iRhythm (IRTC)?

The filing reports 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding.

What type of SEC filing did Capital Research Global Investors submit for IRTC?

They filed an Amendment No. 4 to Schedule 13G/A reporting beneficial ownership in iRhythm Technologies, Inc.

What date is listed as the event requiring the Schedule 13G filing?

The filing cites an event date of 06/30/2025.

Does the filing indicate voting or dispositive power over the reported shares?

Yes. The filing reports sole voting power of 1,506,864 shares and sole dispositive power of 1,506,864 shares.

Did Capital Research state whether the shares were acquired to influence control of iRhythm?

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.
Irhythm Technologies Inc

NASDAQ:IRTC

IRTC Rankings

IRTC Latest News

IRTC Latest SEC Filings

IRTC Stock Data

5.22B
31.77M
1.08%
114.31%
7.77%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
San Francisco